Landos Biopharma falls after Raymond James slashes PT

Landos Biopharma

25/03/2022 14:09

** Drug developer's shares  LABP.O  fall 2.2% to $1.76 after
Raymond James slashes its PT by $15 to $9
    ** Brokerage says the development of co's lead drug 
omilancor for Crohn's disease is "stunted" after it halted a
mid-stage study in January 
    ** Although omilancor remains promising, Landos is in
"rebuild/transition mode" as it searches for a permanent CEO and
reduces headcount - Raymond James
    ** 4 of 7 brokerages rate the stock "buy" or higher, 3
"hold"; their median PT is $22.75
    ** Including Friday's fall, shares down ~63%

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))